{"transactions":[{"id":878860,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-27T21:32:03.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":486000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 26, 2026, the reporting person was awarded 486,000 restricted stock units (\"RSUs\") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date."}],"balance_after":3115547,"source":{"system":"sec-edgar","filing":"0001477932-26-001103","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793226001103/form4.xml","form_type":"4"}},{"id":932902,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-23T21:08:07.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":74700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 17, 2025, the reporting person was awarded 249,000 restricted stock units (\"RSUs\") under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to June 30, 2025 and December 31, 2025 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 74,700 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 24,900 units on each of March 17, 2026, 2027 and 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. The rights with respect to the remaining 174,300 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively."}],"balance_after":2629547,"source":{"system":"sec-edgar","filing":"0001477932-26-000370","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793226000370/form4.xml","form_type":"4"}},{"id":998471,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-17T18:12:19.000Z","date":"2025-11-17","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":0.35,"value":7000.0,"ownership":{"direct":true},"balance_after":2554847,"source":{"system":"sec-edgar","filing":"0001477932-25-008380","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793225008380/form4.xml","form_type":"4"}},{"id":1018954,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-15T20:05:45.000Z","date":"2025-10-14","kind":"purchase","planned":false,"acquired":true,"shares":110000,"price":0.01,"value":1100.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock and accompanying common stock warrants were purchased by the reporting person from the underwriter in connection with an underwritten public offering by the Issuer.  The offering closed on October 14, 2025. The reported sale price reflects the price of $0.52 per share of common stock and accompanying warrant to purchase one additional share of common stock, of which $0.01 of the sale price was allocated to the warrant."}],"balance_after":110000,"derivative":{"exercise_price":0.6,"exercise_date":"2025-10-14","expiration_date":"2030-10-14","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001477932-25-007588","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793225007588/form4.xml","form_type":"4"}},{"id":1018953,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-10-15T20:05:45.000Z","date":"2025-10-14","kind":"purchase","planned":false,"acquired":true,"shares":110000,"price":0.51,"value":56100.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock and accompanying common stock warrants were purchased by the reporting person from the underwriter in connection with an underwritten public offering by the Issuer.  The offering closed on October 14, 2025. The reported sale price reflects the price of $0.52 per share of common stock and accompanying warrant to purchase one additional share of common stock, of which $0.01 of the sale price was allocated to the warrant."}],"balance_after":2534847,"source":{"system":"sec-edgar","filing":"0001477932-25-007588","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793225007588/form4.xml","form_type":"4"}},{"id":1041059,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-15T13:00:07.000Z","date":"2025-09-12","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":0.659,"value":9885.0,"ownership":{"direct":true},"balance_after":2624847,"source":{"system":"sec-edgar","filing":"0001477932-25-006725","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793225006725/form4.xml","form_type":"4"}},{"id":1073705,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-06T13:00:10.000Z","date":"2025-08-05","kind":"purchase","planned":false,"acquired":true,"shares":78125,"price":0.64,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx."}],"balance_after":2609847,"source":{"system":"sec-edgar","filing":"0001477932-25-005494","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793225005494/form4.xml","form_type":"4"}},{"id":1081714,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-07-25T20:01:15.000Z","date":"2025-07-24","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person received 200,000 restricted stock units under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of a closing stock price target above $2.50 per share of the Issuer's common stock for a minimum of thirty consecutive trading days prior to July 24, 2028, which date shall be no earlier than July 24, 2026, and also subject to time-based vesting in a single installment six months after the timely achievement of the target, if at all."}],"balance_after":2531722,"source":{"system":"sec-edgar","filing":"0001477932-25-005250","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793225005250/form4.xml","form_type":"4"}},{"id":1110611,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-06-16T12:27:54.000Z","date":"2025-06-12","kind":"purchase","planned":false,"acquired":true,"shares":12500,"price":0.5898,"value":7372.5,"ownership":{"direct":true},"balance_after":2331722,"source":{"system":"sec-edgar","filing":"0001477932-25-004603","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793225004603/form4.xml","form_type":"4"}},{"id":1144409,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-05-19T16:43:56.000Z","date":"2025-05-19","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":0.4365,"value":8730.0,"ownership":{"direct":true},"balance_after":2319222,"source":{"system":"sec-edgar","filing":"0001477932-25-003959","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793225003959/form4.xml","form_type":"4"}},{"id":1190337,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-27T12:13:46.000Z","date":"2025-03-26","kind":"purchase","planned":false,"acquired":true,"shares":181818,"price":0.55,"value":99999.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx."}],"balance_after":2299222,"source":{"system":"sec-edgar","filing":"0001477932-25-002073","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793225002073/form4.xml","form_type":"4"}},{"id":1290368,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T21:05:58.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options. The \"old\" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The \"replacement\" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options. The \"old\" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The \"replacement\" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant)."}],"balance_after":50000,"derivative":{"exercise_price":3.25,"exercise_date":"2020-02-11","expiration_date":"2029-02-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001477932-25-000614","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793225000614/form4.xml","form_type":"4"}},{"id":1290367,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T21:05:58.000Z","date":"2025-01-29","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options. The \"old\" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The \"replacement\" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options. The \"old\" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The \"replacement\" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant)."}],"balance_after":0,"derivative":{"exercise_price":3.25,"exercise_date":"2020-02-11","expiration_date":"2025-02-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001477932-25-000614","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793225000614/form4.xml","form_type":"4"}},{"id":1338315,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-10T21:01:09.000Z","date":"2024-12-09","kind":"purchase","planned":false,"acquired":true,"shares":139811,"price":0.5722,"value":79999.8542,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx."}],"balance_after":2117404,"source":{"system":"sec-edgar","filing":"0001477932-24-007969","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793224007969/form4.xml","form_type":"4"}},{"id":1417083,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-09-04T20:03:33.000Z","date":"2024-09-01","kind":"grant","planned":false,"acquired":true,"shares":103243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On September 1, 2024, the reporting person was awarded 103,243 restricted stock units (\"RSUs\") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 34,415 units, 34,414 units, and 34,414 units on each of September 1, 2024, October 1, 2024 and November 1, 2024, respectively, are also subject to further time-based vesting in a single installment on June 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested."}],"balance_after":1977593,"source":{"system":"sec-edgar","filing":"0001477932-24-005502","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793224005502/form4.xml","form_type":"4"}},{"id":1432055,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-08-16T20:05:36.000Z","date":"2024-08-15","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On Sept 28, 2023, the reporting person was awarded 118,000 restricted stock units (\"RSUs\") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to Dec 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 29,500 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 9,833 units, 9,833 units, and 9,834 units on each of Sept 28, 2024, 2025 and 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in Jan 2024, the rights with respect to 50,150 RSUs subject to the award previously vested and remain subject to time-based vesting. The rights with respect to the remaining 38,350 RSUs did not vest and were cancelled on August 15, 2024."}],"balance_after":1874350,"source":{"system":"sec-edgar","filing":"0001477932-24-005024","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793224005024/form4.xml","form_type":"4"}},{"id":1494260,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-06-04T20:06:30.000Z","date":"2024-06-01","kind":"grant","planned":false,"acquired":true,"shares":90182,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On June 1, 2024, the reporting person was awarded 90,182 restricted stock units (\"RSUs\") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 30,061 units, 30,061 units, and 30,060 units on each of June 1, 2024, July 1, 2024 and August 1, 2024, respectively, are also subject to further time-based vesting in a single installment on May 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested."}],"balance_after":1844850,"source":{"system":"sec-edgar","filing":"0001477932-24-003488","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793224003488/form4.xml","form_type":"4"}},{"id":1670353,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-26T21:01:38.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":50150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On September 28, 2023, the reporting person was awarded 118,000 restricted stock units (\"RSUs\") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 50,150 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 16,717 units, 16,717 units, and 16,716 units on each of September 28, 2024, September 28, 2025 and September 28, 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested."}],"balance_after":1754668,"source":{"system":"sec-edgar","filing":"0001477932-24-000401","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793224000401/form4.xml","form_type":"4"}},{"id":1717205,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-12-11T13:51:32.000Z","date":"2023-12-08","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.67,"value":6700.0,"ownership":{"direct":true},"balance_after":1704518,"source":{"system":"sec-edgar","filing":"0001477932-23-009055","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793223009055/form4.xml","form_type":"4"}},{"id":1757198,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-10-20T20:02:09.000Z","date":"2023-10-19","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On October 19, 2023, the reporting person was awarded 200,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of a closing stock price target above $5.00 per share of the Issuer's common stock for a minimum of thirty consecutive trading days prior to October 19, 2026, and also subject to time-based vesting in a single installment six months after the timely achievement of the target, if at all.  Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested."}],"balance_after":1694518,"source":{"system":"sec-edgar","filing":"0001477932-23-007778","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793223007778/form4.xml","form_type":"4"}},{"id":1806874,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-08-16T16:28:46.000Z","date":"2023-08-16","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1.22,"value":12200.0,"ownership":{"direct":true},"balance_after":1494518,"source":{"system":"sec-edgar","filing":"0001477932-23-006213","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793223006213/form4.xml","form_type":"4"}},{"id":1833381,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-07-07T20:02:12.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":40050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On October 4, 2022, the reporting person was awarded 89,000 restricted stock units (\"RSUs\") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 40,050 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 13,350 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in October 2022 and January 2023 respectively, the rights with respect to 15,575 RSUs and 33,375 RSUs subject to the award previously vested and remain subject to time-based vesting."}],"balance_after":1484518,"source":{"system":"sec-edgar","filing":"0001477932-23-005117","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793223005117/form4.xml","form_type":"4"}},{"id":2055271,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-13T21:01:20.000Z","date":"2023-01-12","kind":"grant","acquired":true,"shares":33375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On October 4, 2022, the reporting person was awarded 89,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting.  Certain of the performance goals were met, resulting in the rights with respect to 33,375 restricted stock units vesting.  The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 11,125 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively.  Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.  As reported in October 2022, the rights with respect to 15,575 restricted stock units subject to the award previously vested and remain subject to time-based vesting."}],"balance_after":1444468,"source":{"system":"sec-edgar","filing":"0001477932-23-000262","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793223000262/form4.xml","form_type":"4"}},{"id":2137429,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-10-14T20:08:55.000Z","date":"2022-10-13","kind":"grant","acquired":true,"shares":15575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On October 4, 2022, the reporting person was awarded 89,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting.  Certain of the performance goals were met, resulting in the rights with respect to 15,575 restricted stock units vesting.  The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three installments of 5,192 units, 5,192 units, and 5,191 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively.  Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested."}],"balance_after":1411093,"source":{"system":"sec-edgar","filing":"0001477932-22-007704","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793222007704/form4.xml","form_type":"4"}},{"id":2141712,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-10-06T20:05:50.000Z","date":"2022-10-04","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On October 4, 2022, the reporting person was awarded 200,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of a closing stock price target above $5.00 per share of the Issuer's common stock for a minimum of ten consecutive trading days prior to October 4, 2025, and also subject to time-based vesting in a single installment six months after the timely achievement of the target, if at all.  Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested."}],"balance_after":1395518,"source":{"system":"sec-edgar","filing":"0001477932-22-007487","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793222007487/form4.xml","form_type":"4"}},{"id":2171288,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-08-30T15:19:33.000Z","date":"2022-08-30","kind":"purchase","acquired":true,"shares":3500,"price":1.61,"value":5635.0,"ownership":{"direct":true},"balance_after":1195518,"source":{"system":"sec-edgar","filing":"0001477932-22-006512","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793222006512/form4.xml","form_type":"4"}},{"id":2222602,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-24T20:04:12.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":59466,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On August 3, 2021, the reporting person was granted an option to purchase 91,486 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting.  Certain of the performance goals were met, resulting in the rights with respect to 59,466 shares vesting.  The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 29,733 shares on each of August 3, 2022 and August 3, 2023, respectively.  As reported in April 2022, the rights with respect to the remaining 32,020 shares subject to the award previously vested and remain subject to time-based vesting."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On August 3, 2021, the reporting person was granted an option to purchase 91,486 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting.  Certain of the performance goals were met, resulting in the rights with respect to 59,466 shares vesting.  The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 29,733 shares on each of August 3, 2022 and August 3, 2023, respectively.  As reported in April 2022, the rights with respect to the remaining 32,020 shares subject to the award previously vested and remain subject to time-based vesting."}],"balance_after":91486,"derivative":{"exercise_price":3.4,"expiration_date":"2031-08-03","underlying":"Common Stock","underlying_shares":59466},"source":{"system":"sec-edgar","filing":"0001477932-22-004662","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793222004662/form4.xml","form_type":"4"}},{"id":2222601,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-06-24T20:04:12.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":32270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 3, 2021, the reporting person was awarded 49,645 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting.  Certain of the performance goals were met, resulting in the rights with respect to 32,270 restricted stock units vesting.  The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 16,136 units and 16,134 units on each of August 3, 2022 and August 3, 2023, respectively.  Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.  As reported in April 2022, the rights with respect to the remaining 17,375 restricted stock units subject to the award previously vested and remain subject to time-based vesting."}],"balance_after":1192018,"source":{"system":"sec-edgar","filing":"0001477932-22-004662","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793222004662/form4.xml","form_type":"4"}},{"id":2300903,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-08T20:05:37.000Z","date":"2022-04-07","kind":"grant","acquired":true,"shares":32020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On August 3, 2021, the reporting person was granted an option to purchase 91,486 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting.  Certain of the performance goals were met, resulting in the rights with respect to 32,020 shares vesting.  The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 16,010 shares on each of August 3, 2022 and August 3, 2023, respectively."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On August 3, 2021, the reporting person was granted an option to purchase 91,486 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting.  Certain of the performance goals were met, resulting in the rights with respect to 32,020 shares vesting.  The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 16,010 shares on each of August 3, 2022 and August 3, 2023, respectively."}],"balance_after":32020,"derivative":{"exercise_price":3.4,"expiration_date":"2031-08-03","underlying":"Common Stock","underlying_shares":32020},"source":{"system":"sec-edgar","filing":"0001477932-22-002188","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793222002188/form4.xml","form_type":"4"}},{"id":2300902,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-04-08T20:05:37.000Z","date":"2022-04-07","kind":"grant","acquired":true,"shares":17375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 3, 2021, the reporting person was awarded 49,645 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting.  Certain of the performance goals were met, resulting in the rights with respect to 17,375 restricted stock units vesting.  The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 8,687 units and 8,688 units on each of August 3, 2022 and August 3, 2023, respectively.  Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested."}],"balance_after":1159748,"source":{"system":"sec-edgar","filing":"0001477932-22-002188","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793222002188/form4.xml","form_type":"4"}},{"id":2478301,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-10T21:05:22.000Z","date":"2021-12-08","kind":"grant","acquired":true,"shares":85000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable.  The \"replacement\" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable.  The \"replacement\" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant)."}],"balance_after":85000,"derivative":{"exercise_price":3.6,"exercise_date":"2021-04-13","expiration_date":"2030-04-13","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001477932-21-009119","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793221009119/form4.xml","form_type":"4"}},{"id":2478300,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-10T21:05:22.000Z","date":"2021-12-08","kind":"disposition_to_issuer","acquired":false,"shares":85000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable.  The \"replacement\" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable.  The \"replacement\" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant)."}],"balance_after":0,"derivative":{"exercise_price":3.6,"exercise_date":"2021-04-13","expiration_date":"2026-04-13","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001477932-21-009119","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793221009119/form4.xml","form_type":"4"}},{"id":2524076,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-05T20:06:55.000Z","date":"2021-11-03","kind":"grant","acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable.  The \"replacement\" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable.  The \"replacement\" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant)."}],"balance_after":75000,"derivative":{"exercise_price":4,"exercise_date":"2019-01-23","expiration_date":"2028-01-23","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001477932-21-007870","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793221007870/form4.xml","form_type":"4"}},{"id":2524075,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-05T20:06:55.000Z","date":"2021-11-03","kind":"disposition_to_issuer","acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable.  The \"replacement\" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable.  The \"replacement\" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant)."}],"balance_after":0,"derivative":{"exercise_price":4,"exercise_date":"2019-01-23","expiration_date":"2024-01-23","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001477932-21-007870","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793221007870/form4.xml","form_type":"4"}},{"id":2524074,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-05T20:06:55.000Z","date":"2021-11-03","kind":"grant","acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable.  The \"replacement\" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable.  The \"replacement\" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant)."}],"balance_after":100000,"derivative":{"exercise_price":5,"exercise_date":"2018-03-30","expiration_date":"2027-03-30","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001477932-21-007870","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793221007870/form4.xml","form_type":"4"}},{"id":2524073,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-05T20:06:55.000Z","date":"2021-11-03","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable.  The \"replacement\" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable.  The \"replacement\" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant)."}],"balance_after":0,"derivative":{"exercise_price":5,"exercise_date":"2018-03-30","expiration_date":"2023-03-30","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001477932-21-007870","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793221007870/form4.xml","form_type":"4"}},{"id":2524072,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-05T20:06:55.000Z","date":"2021-11-03","kind":"grant","acquired":true,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable.  The \"replacement\" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable.  The \"replacement\" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant)."}],"balance_after":125000,"derivative":{"exercise_price":4,"exercise_date":"2017-04-15","expiration_date":"2026-04-15","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001477932-21-007870","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793221007870/form4.xml","form_type":"4"}},{"id":2524071,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-05T20:06:55.000Z","date":"2021-11-03","kind":"disposition_to_issuer","acquired":false,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable.  The \"replacement\" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable.  The \"replacement\" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant)."}],"balance_after":0,"derivative":{"exercise_price":4,"exercise_date":"2017-04-15","expiration_date":"2022-04-15","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001477932-21-007870","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000147793221007870/form4.xml","form_type":"4"}},{"id":2632741,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-16T20:38:21.000Z","date":"2021-07-14","kind":"grant","acquired":true,"shares":55000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable.  The \"replacement\" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable.  The \"replacement\" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant)."}],"balance_after":55000,"derivative":{"exercise_price":4,"exercise_date":"2016-01-23","expiration_date":"2025-07-23","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001078782-21-000675","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878221000675/primary_doc.xml","form_type":"4"}},{"id":2632740,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-16T20:38:21.000Z","date":"2021-07-14","kind":"disposition_to_issuer","acquired":false,"shares":55000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable.  The \"replacement\" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable.  The \"replacement\" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant)."}],"balance_after":0,"derivative":{"exercise_price":4,"exercise_date":"2016-01-23","expiration_date":"2021-07-23","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001078782-21-000675","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878221000675/primary_doc.xml","form_type":"4"}},{"id":3077346,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-23T20:41:01.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3,"exercise_date":"2016-02-18","expiration_date":"2020-08-18","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001078782-20-000560","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878220000560/primary_doc.xml","form_type":"4"}},{"id":3077345,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-23T20:41:01.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":2.5,"exercise_date":"2015-02-18","expiration_date":"2020-08-18","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001078782-20-000560","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878220000560/primary_doc.xml","form_type":"4"}},{"id":3077344,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-07-23T20:41:01.000Z","date":"2020-07-21","kind":"tax_withholding","acquired":false,"shares":43627,"price":3.95,"value":172326.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the aggregate number of shares of Common Stock retained by VolitionRx for cancellation as payment of the exercise price in a cashless exercise and to satisfy the tax withholding obligations of the Reporting Person. No shares were sold by the Reporting Person or VolitionRx in such cashless exercise transaction."}],"balance_after":1142373,"source":{"system":"sec-edgar","filing":"0001078782-20-000560","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878220000560/primary_doc.xml","form_type":"4"}},{"id":3077343,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-07-23T20:41:01.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":50000,"price":3,"value":150000.0,"ownership":{"direct":true},"balance_after":1186000,"source":{"system":"sec-edgar","filing":"0001078782-20-000560","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878220000560/primary_doc.xml","form_type":"4"}},{"id":3077342,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-07-23T20:41:01.000Z","date":"2020-07-21","kind":"tax_withholding","acquired":false,"shares":40273,"price":3.95,"value":159078.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the aggregate number of shares of Common Stock retained by VolitionRx for cancellation as payment of the exercise price in a cashless exercise and to satisfy the tax withholding obligations of the Reporting Person. No shares were sold by the Reporting Person or VolitionRx in such cashless exercise transaction."}],"balance_after":1136000,"source":{"system":"sec-edgar","filing":"0001078782-20-000560","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878220000560/primary_doc.xml","form_type":"4"}},{"id":3077341,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-07-23T20:41:01.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":50000,"price":2.5,"value":125000.0,"ownership":{"direct":true},"balance_after":1176273,"source":{"system":"sec-edgar","filing":"0001078782-20-000560","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878220000560/primary_doc.xml","form_type":"4"}},{"id":3138457,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-05-22T20:27:46.000Z","date":"2020-05-22","kind":"purchase","acquired":true,"shares":4000,"price":2.75,"value":11000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were purchased by the reporting person in connection with an underwritten public offering by the Issuer. The offering closed on May 22, 2020. The reported sale price reflects the price at which the reporting person purchased the shares from the underwriter."}],"balance_after":1126273,"source":{"system":"sec-edgar","filing":"0001078782-20-000367","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878220000367/primary_doc.xml","form_type":"4"}},{"id":3177004,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-15T20:53:18.000Z","date":"2020-04-13","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"A total of 85,000 Options were granted on April 13, 2020 under the Company's 2015 Stock Incentive Plan.  The Options vest in full twelve months from the date of grant."}],"balance_after":85000,"derivative":{"exercise_price":3.6,"exercise_date":"2021-04-13","expiration_date":"2026-04-13","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001078782-20-000261","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878220000261/primary_doc.xml","form_type":"4"}},{"id":3350515,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-12-06T15:22:22.000Z","date":"2019-12-05","kind":"purchase","acquired":true,"shares":1100,"price":4.24,"value":4664.0,"ownership":{"direct":true},"balance_after":1122273,"source":{"system":"sec-edgar","filing":"0001078782-19-000892","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878219000892/primary_doc.xml","form_type":"4"}},{"id":3662017,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2019-02-13T21:21:12.000Z","date":"2019-02-11","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"A total of 50,000 Options were granted on February 11, 2019 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the grant date."}],"balance_after":50000,"derivative":{"exercise_price":3.25,"exercise_date":"2020-02-11","expiration_date":"2025-02-11","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001078782-19-000126","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878219000126/primary_doc.xml","form_type":"4"}},{"id":3722982,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Option (Right to Buy)","published_at":"2018-12-21T22:32:23.000Z","date":"2018-12-20","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on July 23, 2015 and vested in full at 6 months from the date of grant, and were exercisable for four years from the date first exercisable.  The \"replacement\" options are fully-vested and expire on July 23, 2021."}],"balance_after":55000,"derivative":{"exercise_price":4,"exercise_date":"2016-01-23","expiration_date":"2021-07-23","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001078782-18-001452","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878218001452/primary_doc.xml","form_type":"4"}},{"id":3722981,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Option (Right to Buy)","published_at":"2018-12-21T22:32:23.000Z","date":"2018-12-20","kind":"disposition_to_issuer","acquired":false,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on July 23, 2015 and vested in full at 6 months from the date of grant, and were exercisable for four years from the date first exercisable.  The \"replacement\" options are fully-vested and expire on July 23, 2021."}],"balance_after":0,"derivative":{"exercise_price":4,"exercise_date":"2016-01-23","expiration_date":"2020-01-23","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001078782-18-001452","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878218001452/primary_doc.xml","form_type":"4"}},{"id":3722980,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Option (Right to Buy)","published_at":"2018-12-21T22:32:23.000Z","date":"2018-12-20","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on August 18, 2014 and vested in two equal installments at 6 months and at 18 months from the date of grant, and were exercisable for four years from the date first exercisable.  The \"replacement\" options are fully-vested and both installments expire on August 18, 2020."}],"balance_after":50000,"derivative":{"exercise_price":3,"exercise_date":"2016-02-18","expiration_date":"2020-08-18","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001078782-18-001452","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878218001452/primary_doc.xml","form_type":"4"}},{"id":3722979,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Option (Right to Buy)","published_at":"2018-12-21T22:32:23.000Z","date":"2018-12-20","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on August 18, 2014 and vested in two equal installments at 6 months and at 18 months from the date of grant, and were exercisable for four years from the date first exercisable.  The \"replacement\" options are fully-vested and both installments expire on August 18, 2020."}],"balance_after":50000,"derivative":{"exercise_price":2.5,"exercise_date":"2015-02-18","expiration_date":"2020-08-18","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001078782-18-001452","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878218001452/primary_doc.xml","form_type":"4"}},{"id":3722978,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Option (Right to Buy)","published_at":"2018-12-21T22:32:23.000Z","date":"2018-12-20","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on August 18, 2014 and vested in two equal installments at 6 months and at 18 months from the date of grant, and were exercisable for four years from the date first exercisable.  The \"replacement\" options are fully-vested and both installments expire on August 18, 2020."}],"balance_after":0,"derivative":{"exercise_price":3,"exercise_date":"2016-02-18","expiration_date":"2020-02-18","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001078782-18-001452","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878218001452/primary_doc.xml","form_type":"4"}},{"id":3722977,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Option (Right to Buy)","published_at":"2018-12-21T22:32:23.000Z","date":"2018-12-20","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the \"old\" options and the grant of \"replacement\" options.  The \"old\" options were originally granted on August 18, 2014 and vested in two equal installments at 6 months and at 18 months from the date of grant, and were exercisable for four years from the date first exercisable.  The \"replacement\" options are fully-vested and both installments expire on August 18, 2020."}],"balance_after":0,"derivative":{"exercise_price":2.5,"exercise_date":"2015-02-18","expiration_date":"2019-02-18","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001078782-18-001452","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878218001452/primary_doc.xml","form_type":"4"}},{"id":3841143,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-08-17T14:39:18.000Z","date":"2018-08-16","kind":"purchase","acquired":true,"shares":6500,"price":1.91,"value":12415.0,"ownership":{"direct":true},"balance_after":1121173,"source":{"system":"sec-edgar","filing":"0001078782-18-000886","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878218000886/primary_doc.xml","form_type":"4"}},{"id":4090525,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-25T21:47:40.000Z","date":"2018-01-23","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"A total of 75,000 Options were granted on January 23, 2018 under the Company's 2015 Stock Incentive Plan.  The Options vest in full twelve months from the date of grant."}],"balance_after":75000,"derivative":{"exercise_price":4,"exercise_date":"2019-01-23","expiration_date":"2024-01-23","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001078782-18-000069","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878218000069/primary_doc.xml","form_type":"4"}},{"id":4231849,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-08-17T20:08:34.000Z","date":"2017-08-16","kind":"purchase","acquired":true,"shares":3630,"price":2.77,"value":10055.1,"ownership":{"direct":false,"nature":"Concord International, Inc."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of Common Stock are held directly by Concord International, Inc.  Mr. Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares of Common Stock held by Concord International, Inc."}],"balance_after":1007718,"source":{"system":"sec-edgar","filing":"0001078782-17-001160","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878217001160/primary_doc.xml","form_type":"4"}},{"id":4366215,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-04-03T20:27:37.000Z","date":"2017-03-30","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"A total of 100,000 Options were granted on March 30, 2017 under the Company's 2015 Stock Incentive Plan.  The Options vest in full twelve months from the date of grant."}],"balance_after":100000,"derivative":{"exercise_price":5,"exercise_date":"2018-03-30","expiration_date":"2023-03-30","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001078782-17-000411","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878217000411/primary_doc.xml","form_type":"4"}},{"id":4548114,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-11-21T21:14:57.000Z","date":"2016-11-18","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3,"exercise_date":"2012-11-25","expiration_date":"2016-11-25","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001078782-16-003843","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878216003843/primary_doc.xml","form_type":"4"}},{"id":4548113,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2016-11-21T21:14:57.000Z","date":"2016-11-18","kind":"tax_withholding","acquired":false,"shares":13393,"price":4.48,"value":60000.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation as payment of the exercise price in a cashless exercise.  No shares were sold by the Reporting Person or VolitionRx in such cashless exercise transaction."}],"balance_after":1114673,"source":{"system":"sec-edgar","filing":"0001078782-16-003843","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878216003843/primary_doc.xml","form_type":"4"}},{"id":4548112,"issuer":{"id":8241,"kind":"organization","name":"VOLITIONRX LTD"},"owners":[{"id":64386,"kind":"person","name":"Reynolds Cameron John","position":1,"cik":"0001340610","reported_name":"Reynolds Cameron John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2016-11-21T21:14:57.000Z","date":"2016-11-18","kind":"exercise","acquired":true,"shares":20000,"price":3,"value":60000.0,"ownership":{"direct":true},"balance_after":1128066,"source":{"system":"sec-edgar","filing":"0001078782-16-003843","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/93314/000107878216003843/primary_doc.xml","form_type":"4"}}]}